Eikon Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Eikon Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Millbrae
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EIKN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001861123
- EIN
- 84-2807586
Board of directors
-
David W. Meline · DirectorSince 2026
-
Josh Wolfe · DirectorSince 2026
-
Kenneth C. Frazier · DirectorSince 2026
-
Leon Chen · DirectorSince 2026
-
Ma. Fatima Francisco · DirectorSince 2026
-
Robert Luther Huffines · DirectorSince 2026
-
Roger M. Perlmutter · Director · See remarksSince 2026
Board connections
3 of this board's directors also sit on 5 other boards.
- via David W. Meline and Ma. Fatima Francisco
- via Robert Luther Huffines
- via Robert Luther Huffines
- via Ma. Fatima Francisco
- via David W. Meline
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $52,150,649
- 10 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | Column Group IV GP, LP 10% owner | Open-market purchase | +89,200 | $11.56 | $1,031,045 |
| Feb 6, 2026 | Roger M. Perlmutter Director, Officer (See remarks) | Derivative conversion | +284,857 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +1,296,629 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +1,403,568 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +110,928 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,387,705 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,387,705 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +44,249 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +1,151,540 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +1,151,540 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +47,898 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,155,765 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,155,765 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +3,785 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +688,283 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.